Ecs Botanics Holdings Ltd (AU:ECS) has released an update.
ECS Botanics Holdings Ltd has initiated a direct-to-consumer strategy with its first B2C medicinal cannabis contract under the ‘RAP’ brand, aiming for a minimum of $380,000 in annual sales. The company has expanded its GMP license to include a wider range of products, such as gummies and soft gel capsules, and has begun commercial shipments to Germany. To support the launch, ECS has also recruited an experienced B2C sales team and expects revenue growth and increased margins in 2025.
For further insights into AU:ECS stock, check out TipRanks’ Stock Analysis page.
